PHASE 1 CLINICAL TRIAL EVALUATING AN AUTOLOGOUS BRAIN TUMOR STEM CELL RNA BASED DENDRITIC CELL VACCINE FOR THE TREATMENT OF MALIGNANT GLIOMA. PATIENTS WILL RECEIVE A PERSONALIZED DENDRITIC CELL VACCINE TO ELICIT AN IMMUNE RESPONSE AGAINST THEIR TUMORS IN CONJUNCTION WITH A PROGRAMMED CELL DEATH 1 (PD-1) INHIBITOR.

PIs: Charles S. Cobbs, M.D.
Director, Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute

Parvinder Hothi, Ph.D.
Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute

Close Menu